Who to call at Beacon Biosignals, and when
Fundz watches for the moments Beacon Biosignals starts buying, and tells you who to reach.
- An alert the day Beacon Biosignals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Beacon Biosignals, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2
Beacon Biosignals and Skye Bioscience, Inc. Collaborate to Enhance CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
Jul 24, 2024
Contract Type
partnership
BostonInformation TechnologySoftwareDescription
Beacon Biosignals announced a strategic collaboration with Skye Bioscience, Inc. to incorporate sleep quality and sleep apnea endpoints in the CBEYOND™ Phase 2 clinical trial of Nimacimab for addressing obesity and cardiometabolic disease. The collaboration aims to better understand the comprehensive impact of Nimacimab on patients with obesity by integrating advanced sleep monitoring technology.
Related People
Agreement Insights
What this usually meansStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Beacon Biosignals signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.